Read this statement on using bamlanivimab plus etesevimab in nonhospitalized patients with COVID-19.
The Panel offers suggestions for prioritizing these agents when there are logistical constraints.
Casirivimab plus imdevimab can be used as PEP in people who meet the criteria in the updated EUA.
These sections summarize the data on remdesivir, chloroquine, and other antiviral medications.
These sections summarize the data on monoclonal antibodies, convalescent plasma, and SARS-CoV-2 immunoglobulins.
Review the data on the use of mesenchymal stem cells for the treatment of COVID-19.
These sections summarize the data on IL-6 inhibitors, kinase inhibitors, and other immunomodulators.
This section discusses screening, prevention, and treatment for thromboembolism in people with COVID-19.
Review the data on using certain concomitant therapies in people with COVID-19.
These sections discuss the rationale for using supplements in people with COVID-19.